TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
TP53失活是骨肉瘤(OS)发生中的关键事件,也是其侵袭性的基础,但其在肿瘤-免疫相互作用中的作用仍知之甚少。
英文原题:Characterization of Carcinogenesis Resistance in Anatolian Blind Mole-rat Mesenchymal Stem Cells and Assessment of Transcriptomic Signatures.
间充质干细胞(MSCs)在肿瘤进展和治疗耐药中表现出双重作用。
间充质干细胞(MSCs)在肿瘤进展和治疗耐药中表现出双重作用。然而,盲鼹鼠(BMR,Nannospalax xanthodon)对自发性和诱发性癌变具有非凡的天然抵抗力,使其MSCs成为具有重要治疗意义的研究对象。本研究探讨了BMR MSCs和成纤维细胞对致癌物N-甲基-N-亚硝基脲(MNU)的抵抗力。我们检测了从盲鼹鼠中分离并表征的骨髓来源MSCs以及成纤维细胞在暴露于化学致癌物MNU后的细胞行为和转录组表达差异。对小鼠、大鼠和人来源的MSCs也进行了类似分析,并评估了物种间的表达差异。
Mesenchymal stem cells (MSCs) exhibit dual roles in tumor progression and therapy resistance. However, the blind mole-rat (BMR, Nannospalax xanthodon) exhibits extraordinary natural resistance to spontaneous and induced carcinogenesis, making its MSCs a subject of significant therapeutic interest. This study investigates BMR MSCs' and fibroblasts' resistance to the carcinogen N-methyl-N-nitrosourea (MNU). We examined the cellular behavior and transcriptomic expression differences of bone marrow-derived MSCs and also fibroblasts isolated and characterized from blind mole-rats after exposure to the chemical carcinogen MNU. Similar analyses were also performed on mouse, rat, and human-derived MSCs, and expression disparities between species were evaluated. While MNU treatment significantly induced apoptosis and reduced cell viability in human and mouse MSCs, BMR MSCs maintained stable proliferation kinetics, viability, and multi-lineage differentiation potential. Transcriptomic profiling revealed species-specific gene expression patterns, highlighting unique adaptive responses in the BMR. In BMR fibroblasts, MNU treatment suppressed PI3K/Akt signaling and modulated mitochondrial oxidative phosphorylation, whereas BMR MSCs demonstrated a flexible signaling architecture that preserved cellular programming and p53-mediated transcriptional regulation. Cross-species analysis integrated with TCGA datasets identified LAMTOR3 as a critical p53-dependent tumor-protective node. The ability of BMR MSCs to maintain the p53-LAMTOR3 axis following MNU treatment, alongside the suppression of pro-tumoral SMAD signaling, suggests a robust evolutionary strategy to inhibit malignant transformation. These findings provide novel insights into the genomic integrity of the BMR and identify potential biomarkers and therapeutic targets for enhancing cancer resistance.
MEMBER ACCOUNT
登录成功会直接打开下一页。